Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 May;71(5):1230–1239. doi: 10.1172/JCI110872

Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.

W L Sibbitt Jr, P M Mathews, A D Bankhurst
PMCID: PMC436983  PMID: 6853711

Abstract

Spontaneous cytotoxicity mediated by natural killer (NK) cells is impaired in several human diseases including systemic lupus erythematosus (SLE). The precise mechanism(s) by which NK activity is suppressed in patients with SLE is generally unknown. The present study was designed to focus on cellular defects per se in NK cells from patients with SLE. It was observed that the usual enhancing effect of interferon (IF) and IF inducers was markedly impaired in SLE patients. Of 24 SLE patients studied, 17 had significantly decreased NK activity relative to controls. NK activity had a significant negative correlation with clinical activity score (r = -0.56, P less than 0.005) but was not correlated with corticosteroid dose, antinuclear antibody titers, total hemolytic complement (CH50), or sedimentation rate. Furthermore, significant depressions in NK activity correlated with variations in disease activity in six patients followed serially. Depressed NK function could not be reversed by prolonged in vitro incubation at 37 degrees C or with protease treatment. Furthermore, depressed NK activity was not altered by removal of glass adherent cells nor was a suppression of NK activity in normal controls seen by the addition of SLE peripheral mononuclear cells. No reversal of depressed activity to normal levels was seen by the addition of indomethacin nor did the supernatants from SLE cell cultures cause a suppression of normal NK function. NK activity in SLE patients did not respond normally to IF inducers (poly-I:C and concanavalin A) even if the SLE patients had normal NK function. The response of SLE cells to exogenous IF was also impaired. The number of effector-target conjugates was quantitated with several target cells (K562, Yac-1, Fravel) in SLE patients and controls. A significant correlation between the proportion of glass nonadherent mononuclear cells that formed effector-target conjugates with these various targets and the magnitude of NK lysis was observed. However, SLE and normal subjects had equal numbers of effector-target conjugates independent of NK function. Release of a soluble cytotoxic factor was induced with concanavalin A, and was markedly impaired in SLE patients relative to normal controls. Thus, impaired NK cell function in SLE does not appear to be related to cell-mediated suppressive mechanisms or to the deletion of effector cells; rather, the decreased NK activity may be related to an impaired release of a soluble cytotoxic factor.

Full text

PDF
1230

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abo T., Balch C. M. A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol. 1981 Sep;127(3):1024–1029. [PubMed] [Google Scholar]
  2. Bankhurst A. D. The modulation of human natural killer cell activity by prostaglandins. J Clin Lab Immunol. 1982 Feb;7(2):85–91. [PubMed] [Google Scholar]
  3. Barada F. A., Jr, Andrews B. S., Davis J. S., 4th, Taylor R. P. Antibodies to Sm in patients with systemic lupus erythematosus. Correlation of Sm antibody titers with disease activity and other laboratory parameters. Arthritis Rheum. 1981 Oct;24(10):1236–1244. doi: 10.1002/art.1780241003. [DOI] [PubMed] [Google Scholar]
  4. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  5. Decker J. L., Steinberg A. D., Reinertsen J. L., Plotz P. H., Balow J. E., Klippel J. H. NIH conference. Systemic lupus erythematosus: evolving concepts. Ann Intern Med. 1979 Oct;91(4):587–604. doi: 10.7326/0003-4819-91-4-587. [DOI] [PubMed] [Google Scholar]
  6. Fauci A. S., Moutsopoulos H. M. Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum. 1981 Apr;24(4):577–583. doi: 10.1002/art.1780240402. [DOI] [PubMed] [Google Scholar]
  7. Fitzharris P., Alcocer J., Stephens H. A., Knight R. A., Snaith M. L. Insensitivity to interferon of NK cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 1982 Jan;47(1):110–118. [PMC free article] [PubMed] [Google Scholar]
  8. Fujimiya Y., Babiuk L. A., Rouse B. T. Direct lymphocytotoxicity against herpes simplex virus infected cells. Can J Microbiol. 1978 Sep;24(9):1076–1081. doi: 10.1139/m78-177. [DOI] [PubMed] [Google Scholar]
  9. Goto M., Tanimoto K., Chihara T., Horiuchi Y. Natural cell-mediated cytotoxicity in Sjögren's syndrome and rheumatoid arthritis. Arthritis Rheum. 1981 Nov;24(11):1377–1382. doi: 10.1002/art.1780241107. [DOI] [PubMed] [Google Scholar]
  10. Goto M., Tanimoto K., Horiuchi Y. Natural cell mediated cytotoxicity in systemic lupus erythematosus: suppression by antilymphocyte antibody. Arthritis Rheum. 1980 Nov;23(11):1274–1281. doi: 10.1002/art.1780231108. [DOI] [PubMed] [Google Scholar]
  11. Hamilton M. E., Winfield J. B. Tgamma cells in systemic lupus erythematosus. Variation with disease activity. Arthritis Rheum. 1979 Jan;22(1):1–6. doi: 10.1002/art.1780220101. [DOI] [PubMed] [Google Scholar]
  12. Herberman R. B., Holden H. T. Natural killer cells as antitumor effector cells. J Natl Cancer Inst. 1979 Mar;62(3):441–445. doi: 10.1093/jnci/62.3.441. [DOI] [PubMed] [Google Scholar]
  13. Hersey P., Edwards A., McCarthy W. H. Tumour-related changes in natural killer cell activity in melanoma patients. Influence of stage of disease, tumour thickness and age of patients. Int J Cancer. 1980 Feb 15;25(2):187–194. doi: 10.1002/ijc.2910250204. [DOI] [PubMed] [Google Scholar]
  14. Hoffman T. Natural killer funciton in systemic lupus erythematosus. Arthritis Rheum. 1980 Jan;23(1):30–35. doi: 10.1002/art.1780230106. [DOI] [PubMed] [Google Scholar]
  15. Holm G., Björkholm M., Johansson B., Mellstedt H., Lindemalm C. Monocyte function in Hodgkin's disease. Clin Exp Immunol. 1982 Jan;47(1):162–168. [PMC free article] [PubMed] [Google Scholar]
  16. Horwitz D. A., Juul-Nielsen K. Human blood L lymphocytes in patients with active systemic lupus erythematosus, rheumatoid arthritis and scleroderma: a comparison with T and B cells. Clin Exp Immunol. 1977 Dec;30(3):370–378. [PMC free article] [PubMed] [Google Scholar]
  17. Kadish A. S., Doyle A. T., Steinhauer E. H., Ghossein N. A. Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease. J Immunol. 1981 Nov;127(5):1817–1822. [PubMed] [Google Scholar]
  18. Karsh J., Dorval G., Osterland C. K. Natural cytotoxicity in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1981 Jun;19(3):437–446. doi: 10.1016/0090-1229(81)90086-6. [DOI] [PubMed] [Google Scholar]
  19. Klein E., Ben-Bassat H., Neumann H., Ralph P., Zeuthen J., Polliack A., Vánky F. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer. 1976 Oct 15;18(4):421–431. doi: 10.1002/ijc.2910180405. [DOI] [PubMed] [Google Scholar]
  20. Marx J. L. Natural killer cells help defend the body. Science. 1980 Nov 7;210(4470):624–626. doi: 10.1126/science.6159684. [DOI] [PubMed] [Google Scholar]
  21. Merrill J. E., Ullberg M., Jondal M. Influence of IgG and IgM receptor triggering on human natural killer cell cytotoxicity measured on the level of the single effector cell. Eur J Immunol. 1981 Jul;11(7):536–541. doi: 10.1002/eji.1830110703. [DOI] [PubMed] [Google Scholar]
  22. Neighbour P. A., Grayzel A. I. Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Immunol. 1981 Sep;45(3):576–582. [PMC free article] [PubMed] [Google Scholar]
  23. Neighbour P. A., Grayzel A. I. Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Immunol. 1981 Sep;45(3):576–582. [PMC free article] [PubMed] [Google Scholar]
  24. Roder J. C., Argov S., Klein M., Petersson C., Kiessling R., Andersson K., Hansson M. Target-effector cell interaction in the natural killer cell system. V. Energy requirements, membrane integrity, and the possible involvement of lysosomal enzymes. Immunology. 1980 May;40(1):107–116. [PMC free article] [PubMed] [Google Scholar]
  25. Roder J. C., Haliotis T., Klein M., Korec S., Jett J. R., Ortaldo J., Heberman R. B., Katz P., Fauci A. S. A new immunodeficiency disorder in humans involving NK cells. Nature. 1980 Apr 10;284(5756):553–555. doi: 10.1038/284553a0. [DOI] [PubMed] [Google Scholar]
  26. Roder J. C., Klein M. Target-effector interaction in the natural killer cell system. IV. Modulation by cyclic nucleotides. J Immunol. 1979 Dec;123(6):2785–2790. [PubMed] [Google Scholar]
  27. Silva A., Bonavida B., Targan S. Mode of action of interferon-mediated modulation of natural killer cytotoxic activity: recruitment of pre-NK cells and enhanced kinetics of lysis. J Immunol. 1980 Aug;125(2):479–484. [PubMed] [Google Scholar]
  28. Targan S., Grimm E., Bonavida B. A single cell marker of active NK cytotoxicity: only a fraction of target binding lymphocytes are killer cells. J Clin Lab Immunol. 1980 Nov;4(3):165–168. [PubMed] [Google Scholar]
  29. Timonen T., Ortaldo J. R., Herberman R. B. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med. 1981 Mar 1;153(3):569–582. doi: 10.1084/jem.153.3.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Timonen T., Saksela E., Ranki A., Häyry P. Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity against cell-line targets. Cell Immunol. 1979 Nov;48(1):133–148. doi: 10.1016/0008-8749(79)90106-0. [DOI] [PubMed] [Google Scholar]
  31. Ullberg M., Merrill J., Jondal M. Interferon-induced NK augmentation in humans. An analysis of target recognition, effector cell recruitment and effector cell recycling. Scand J Immunol. 1981 Sep;14(3):285–292. doi: 10.1111/j.1365-3083.1981.tb00566.x. [DOI] [PubMed] [Google Scholar]
  32. Winchester R. J., Winfield J. B., Siegal F., Wernet P., Bentwich Z., Kunkel H. G. Analyses of lymphocytes from patients with rheumatoid arthritis and systemic lupus erythematosus. Occurrence of interfering cold-reactive antilymphocyte antibodies. J Clin Invest. 1974 Nov;54(5):1082–1092. doi: 10.1172/JCI107852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wright S. C., Bonavida B. Selective lysis of NK-sensitive target cells by a soluble mediator released from murine spleen cells and human peripheral blood lymphocytes. J Immunol. 1981 Apr;126(4):1516–1521. [PubMed] [Google Scholar]
  34. Wright S. C., Bonavida B. Studies on the mechanism of natural killer (NK) cell-mediated cytotoxicity (CMC). I. Release of cytotoxic factors specific for NK-sensitive target cells (NKCF) during co-culture of NK effector cells with NK target cells. J Immunol. 1982 Jul;129(1):433–439. [PubMed] [Google Scholar]
  35. Yam L. T., Li C. Y., Crosby W. H. Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol. 1971 Mar;55(3):283–290. doi: 10.1093/ajcp/55.3.283. [DOI] [PubMed] [Google Scholar]
  36. Zarling J. M., Schlais J., Eskra L., Greene J. J., Ts'o P. O., Carter W. A. Augmentation of human natural killer cell activity by polyinosinic acid-polycytidylic acid and its nontoxic mismatched analogues. J Immunol. 1980 Apr;124(4):1852–1857. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES